Hiroyuki Okuzawa Representative Director, President & COO Koji Ogawa Executive Officer, CFO Ken Takeshita Global R&D Head Yuki Abe Corporate Officer, Head of R&D Division PLAY LIST from the beginning FY2024 Q3 Financial Results Presentation Forward Looking Statements 1. FY2024 Q3 Financial Results Overview of FY2024 Q3 Results Revenue Core Operating Profit Profit Attributable to Owners of the Company 2. FY2024 Forecast Revision to the forecast 3. Business Update Performance Approved in Japan and the US Acquisition of Intellectual Property Rights for Anti-TA-MUC1 Antibody Information: Oncology Business Briefing 4. R&D Update 5DXd ADCs Update Approval of New Indication for Breast Cancer 1L Treatment for HER2+ Gastric Cancer Breast Update:First approval of DATROWAY Lung Update Pooled Analysis of TROPION-Lung05 and TROPION-Lung01 Investigating Optimal Treatment Sequence of DXd ADCs Expand Target Indications to ESCC Investigate Possibilities beyond Platinum-Resistant Ovarian Cancer Other Clinical Updates Next Wave Update QuANTUM-Wild Study Design IO Combination for NSCLC Plan to Start a Clinical Study for New Tcell Engager News Flow FY2024 and FY2025 News Flow Appendix Revenue: Business Units (incl. Forex Impact) Revenue: Major Products in Japan 5DXd ADCs Revenue (incl. Forex Impact) 5DXd ADCs Upfront and Milestone Payments Major R&D Milestones (ENHERTU Major R&D Milestones (DATROWAY Major R&D Milestones(HER3 DXd, I DXd, R DXd) Major R&D Milestones (Next Wave) Major R&D Pipeline: 5DXd ADCs(1) Major R&D Pipeline: 5DXd ADCs(2) Major R&D Pipeline: Next Wave @ Q&A Q&A 1 Q&A 2 Q&A 3 Q&A 4 Q&A 5 Q&A 6 Q&A 7 Q&A 8 Back Next